Early detection of comorbidity in psoriasis: Recommendations of the National Conference on Healthcare in Psoriasis;Früherkennung der Komorbidität bei Psoriasis: Konsensusempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis

JDDG - Journal of the German Society of Dermatology

Volumn 13, Issue 7, 2015, Pages

  Radtke, Marc Alexander ^a   Mrowietz, Ulrich ^b   Feuerhahn, Julia ^a   Härter, Martin ^a   Von Kiedrowski, Ralph ^c   Nast, Alexander ^d   Reich, Kristian ^e   Strömer, Klaus ^f   Wohlrab, Johannes ^g   Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Dermatologische Praxis   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Dermatologikum Hamburg   (Germany)

^f Praxis F Dermatol A   (Germany)

^g MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL ABUSE; ALGORITHM; ARTICLE; COMORBIDITY; DEPRESSION; DERMATOLOGIST; DIABETES MELLITUS; DYSLIPIDEMIA; EARLY DIAGNOSIS; HUMAN; HYPERTENSION; INFLAMMATORY BOWEL DISEASE; LYMPHOMA; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PSORIASIS; PSORIATIC ARTHRITIS; SCREENING; TOBACCO DEPENDENCE; COMPLICATION; DERMATOLOGY; GERMANY; MASS SCREENING; PRACTICE GUIDELINE; STANDARDS;

ALGORITHMS; DERMATOLOGY; EARLY DIAGNOSIS; GERMANY; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PSORIASIS;

EID: 84933501827     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12643     Document Type: Article

References (54)

1. Torres T, Sales R, Vasconcelos C et al. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 2013; 40: 923-6.
2. Ruiz M, Valdés P, Tomecki K. Selected skin diseases with systemic involvement. Skin Therapy Lett 2013; 18: 1-4.
3. Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med 2014; 127: 12-8.
4. Yeung H, Takeshita J, Mehta NN et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149: 1173-9.
5. Augustin M, Reich K, Glaeske G, Schaefer I et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-51.
6. Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-6.
7. Calamita AB, Calamita Z, Braga JC. Risk factors for cardiovascular disease in psoriasis: relation to inflammation assessed by the severity and duration of illness. Inflamm Allergy Drug Targets 2013; 12: 385-90.
8. Augustin M, Glaeske G, Schäfer I et al. Processes of psoriasis health care in Germany-long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 2012; 10: 648-55.
9. Cooper LT, Baughman KL, Feldman AM et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007; 28: 3076-93.
10. Deutsche Hochdruckliga e. V., DEUTSCHE HYPERTONIE. Leitlinien zur Behandlung der arteriellen Hypertonie. AWMF Register-Nr. 046/001; Available from: http://www.awmf. org/uploads/tx-szleitlinien/046-001-S2-Behandlung-der-arteriellen-Hypertonie-abgelaufen.pdf.
11. Daudén E, Castañeda S, Suárez C, Garciá-Campayo J et al. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermosifiliogr 2012; 103 Suppl 1: 1-64.
12. Wohlrab J, Fiedler G, Gerdes S et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013; 305: 91-8.
13. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens 2003; 21: 1983-92.
14. Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int 2010; 107: 866-73.
15. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-6.
16. Farrell GC, McCullough AJ, Day CP (eds.). Non-Alcoholic Fatty Liver Disease: A Practical Guide. Wiley-Blackwell, Chichester, 2013.
17. Nast A, Boehncke W, Mrowietz U et al. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10 Suppl 2: S1-95.
18. Hildrum B, Mykletun A, Hole T et al. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 2007; 7: 220.
19. Fodor JG, Frohlich JJ, Genest JJ, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000; 162: 1441-7.
20. Hauner H, Buchholz G, Hamann A et al. S3-Leitlinie: Interdisziplinäre Leitlinie der Qualität S3 zur Prävention und Therapie der Adipositas. AWMF-Register Nr. 050/001. http://www.awmf.org/uploads/tx-szleitlinien/050-001l-S3-Adipositas-Prävention-Therapie-2014-11.pdf
21. Huxley R, Mendis S, Zheleznyakov E et al. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010; 64: 16-22.
22. Church T. Exercise in obesity, metabolic syndrome, and diabetes. Prog Cardiovasc Dis 2011; 53: 412-8.
23. Kerner W, Brückel J. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie 2011: 107-11.
24. American Diabetes Association, Clinical Practice Recommendations. Standards of Medical Care in Diabetes-2012; Available from: DOI: 10.2337/dc12-s01.
25. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care Jan 2010; 33(Suppl 1): S62-S69.
26. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
27. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010; 23: 137-43.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2 486-97.
29. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
30. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
31. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366(9491): 1059-62.
32. Guinhouya BC, Samouda H, Zitouni D et al. Evidence of the influence of physical activity on the metabolic syndrome and/or on insulin resistance in pediatric populations: a systematic review. Int J Pediatr Obes 2011; 6: 361-88.
33. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011; 25: 383-91.
34. Bernsmeier C, Heim MH. Nicht-alkoholische Fettleber und Steatohepatitis: hepatitische Manifestation des metabolischen Syndroms. Schweiz Med Forum 2011; 11: 53-7.
35. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
36. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12: 439-45.
37. Bush K, Kivlahan DR, McDonell MB et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158: 1789-95.
38. Kimball AB, Wu EQ, Guérin A et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012; 67: 651-7.e1-2.
39. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(2): 201-17.
40. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007; 120: 953-9.
41. Armstrong AW, Armstrong EJ, Fuller EN. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011; 165: 1162-8.
42. Ronksley PE, Brien SE, Turner BJ et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: 671.
43. Brien SE, Ronksley PE, Turner BJ et al. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011; 342: d636.
44. Adamzik K, McAleer MA, Kirby B. Alcohol and psoriasis: sobering thoughts. Clin Exp Dermatol 2013; 38: 819-22.
45. Hoffmann JC, Preiss JC, Autschbach F et al. S3-Leitlinie., Diagnostik und Therapie des Morbus Crohn". Z Gastroenterol 2008; 46: 1094-146.
46. Boehncke WH, Qureshi A, Merola JF et al. Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol 2014; 170: 772-86.
47. Gladman DD, Mease PJ, Healy P et al. Outcome measures in psoriatic arthritis. J Rheumatol 2007; 34: 1159-66.
48. Radtke MA, Reich K, Blome C et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009; 23: 683-91.
49. Husni ME, Meyer KH, Cohen DS et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581-7.
50. Gladman DD, Schentag CT, Tom BD et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009; 68: 497-501.
51. Härle P, Hartung W, Lehmann P et al. GEPARD-Patientenfragebogen: Erfassung von Patienten mit Psoriasisarthritis aus einem ambulanten dermatologischen Patientenpool. Z Rheumatol 2010; 69: 157-160, 162-3.
52. Boehncke WH, Kirby B, Fitzgerald O, van de Kerkhof PC. New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. J Eur Acad Dermatol Venereol 2014; 28: 264-70.
53. Boehncke W, Boehncke S. Komorbiditäten der Arthritis psoriatica. Z Rheumatol 2013; 72: 779-83.
54. Vasey F, Espinoza LR. Psoriatic arthropy. In: Calin A: Spondylarthropathies. Orlando (Florida): Grune & Stratton, 1984: 151-85.